Da Qing Offspring Study
Launched by CHINA-JAPAN FRIENDSHIP HOSPITAL · Apr 27, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Spouses of the original Daqing diabetes Prevention Research Population (IGT), offspring 1 to 3 generations, and offspring spouses were included in the study, without special restrictions on subjects' gender, age, basic disease status, etc。
- • Conduct a death agent investigation for some deceased members.
- Exclusion Criteria:
- • ▪People who are unwilling to participate in this study
About China Japan Friendship Hospital
China-Japan Friendship Hospital is a leading clinical research institution dedicated to advancing healthcare through innovative medical research and trials. Established as a collaborative effort between China and Japan, the hospital integrates cutting-edge technology with traditional medical practices, fostering a multidisciplinary approach to patient care and clinical studies. The institution is committed to enhancing therapeutic outcomes and improving patient safety while adhering to rigorous ethical standards. With a diverse team of experienced healthcare professionals and researchers, China-Japan Friendship Hospital plays a pivotal role in addressing global health challenges and contributing to medical knowledge through its extensive clinical trial programs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Liping Yu, Doctor
Principal Investigator
China-Japan Friendship Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported